Trials / Conditions / Neoplasms, Colorectal

Neoplasms, Colorectal

26 registered clinical trials studyying Neoplasms, Colorectal — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other An NCT07213609	GlaxoSmithKline	Phase 1 / Phase 2
Active Not Recruiting	A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in C NCT06710847	GlaxoSmithKline	Phase 1 / Phase 2
Active Not Recruiting	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutati NCT05358249	Novartis Pharmaceuticals	Phase 1 / Phase 2
Completed	Study of ESG401 in Adults With Solid Tumors NCT04892342	Shanghai Escugen Biotechnology Co., Ltd	Phase 1 / Phase 2
Recruiting	Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesion NCT04593407	José Carlos Marín Gabriel	N/A
Unknown	Self-expandable Metal Stent (SEMS) Endoscopic Placement for Malignant Colonic Obstruction Therapy NCT05643989	Russian Society of Colorectal Surgeons	N/A
Completed	Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confineme NCT06118125	University of Bordeaux	—
Active Not Recruiting	Physically Active During Cancer Treatment (FAKT) NCT03885817	St. Olavs Hospital	N/A
Active Not Recruiting	9-ING-41 in Patients With Advanced Cancers NCT03678883	Actuate Therapeutics Inc.	Phase 2
Completed	A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorecta NCT03428958	NuCana plc	Phase 1 / Phase 2
Completed	AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test NCT03688906	Freenome Holdings Inc.	—
Unknown	Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients NCT01157052	AHS Cancer Control Alberta	Phase 1
Unknown	A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway NCT02395224	Norwegian University of Science and Technology	—
Completed	A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer NCT02176746	Fuda Cancer Hospital, Guangzhou	Phase 1 / Phase 2
Completed	Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI) NCT01671592	Pawel Kalinski	Phase 1
Terminated	Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer NCT01545141	Roswell Park Cancer Institute	Phase 1 / Phase 2
Withdrawn	A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin NCT01157039	AHS Cancer Control Alberta	Phase 2
Completed	Green Tea Extracts for the Prevention of Colorectal Adenomas and Colorectal Cancer NCT02321969	Seoul National University Hospital	N/A
Completed	Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorec NCT01139138	The Queen Elizabeth Hospital	Phase 1 / Phase 2
Completed	Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Li NCT00967616	Daiichi Sankyo	Phase 2
Completed	Nelfinavir, a Phase I/Phase II Rectal Cancer Study NCT00704600	Maastricht Radiation Oncology	Phase 1 / Phase 2
Completed	A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Color NCT00920803	Sirtris, a GSK Company	Phase 1
Completed	Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Color NCT00536809	GlaxoSmithKline	Phase 1
Completed	Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer NCT00540943	GlaxoSmithKline	Phase 1
Completed	A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After NCT00478634	Novartis Pharmaceuticals	Phase 1
Completed	Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Ox NCT00387387	GlaxoSmithKline	Phase 1